AbbVie posts weak sales of newer drugs as Humira faces fresh competition, shares fall

By Patrick Wingrove and Leroy Leo (Reuters) -AbbVie Inc on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker’s attempts to cushion the blow to sales from fresh competition for its flagship arthritis drug Humira. The company’s shares tumbled more than 8% as investors shrugged off a raised full-year profit…

Read More

China Evergrande gains more than 77% backing of Class A debt holders for debt restructuring incentive

HONG KONG (Reuters) – Embattled property developer China Evergrande Group said on Thursday that holders of more than 77% of its Class A offshore debt by value submitted support for its restructuring proposal, and it would extend the deadline for receiving an incentive to 5:00 p.m. Hong Kong time on May 18. Term sheets published…

Read More